CoChat
Sign Up
Cited by 173Adrenal and Paraganglionic TumorsAdrenal Hormones and DisordersNeuroendocrine Tumor Research Advances

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study

Open access
Hermsen, Ilse G., Fassnacht, Martin, Terzolo, Massimo, Houterman, Saskia, den Hartigh, Jan, Leboulleux, Sophie, Daffara, Fulvia, Berruti, Alfredo, Chadarevian, Rita, Schlumberger, Martin, Allolio, Bruno, Haak, Harm R., Baudin, Eric·2011·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2010-2676
Open this paper in CoChat — free account

Abstract

CONTEXT: In patients with adrenocortical carcinoma (ACC) mitotane activity has been suggested to depend on plasma levels 14 mg/liter or greater and metabolite formation. OBJECTIVE: The study was performed to confirm the correlation of the currently used mitotane (o,p'DDD) threshold of 14 mg/liter with tumor response and to evaluate the additional value of 1,1-(o,p'-dichlorodiphenyl) acetic acid (o,p'DDA) and o,p'DDE (1,1-(o,p'-dichlorodiphenyl)-2,2 dichloroethene) levels for predicting tumor response. SUBJECTS/METHODS: Plasma samples collected within 3 months of best response from 91 patients on mitotane therapy for advanced ACC were analyzed retrospectively. O,p'DDD and metabolites were assessed and related to tumor response and survival. Receiver operating characteristic curves were used. Sensitivity and specificity were calculated for different cutoff levels of o,p'DDD and metabolites. RESULTS: Objective tumor response was observed in 19% of patients. Median o,p'DDD level was higher in responders (P = 0.03). More responders were found among patients achieving o,p'DDD levels 14 mg/liter or greater (P = 0.02). Univariate and multivariate analysis showed significantly longer survival for patients with o,p'DDD levels 14 mg/liter or greater (hazard ratio 0.52, P = 0.04, hazard ratio 0.46, P = 0.03). An o,p'DDD cutoff value of 14 mg/liter was associated with a sensitivity of 65% and specificity 69%. An o,p'DDD level 20 mg/liter or greater or 14 mg/liter or greater combined with o,p'DDA level 92 mg/liter or greater was associated with a specificity of 90 and 92%, respectively. CONCLUSIONS: Our data confirm the value of o,p'DDD plasma monitoring as well as targeting the 14 mg/liter cutoff level in the therapeutic management of ACC patients. Furthermore, our results suggest additional benefit of higher levels of o,p'DDD and combined measurement of o,p'DDD and o,p'DDA.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2010-2676

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 36 references

Cited by

Sorted by citations

Items 101–173 of 173

Related

See all

Metadata

Authors
Hermsen, I. G., Fassnacht, M., Terzolo, M., Houterman, S., den Hartigh, J., Leboulleux, S., Daffara, F., Berruti, A., Chadarevian, R., Schlumberger, M., Allolio, B., Haak, H. R., & Baudin, E.
Affiliations
  • Máxima Medisch Centrum (NL)
  • University of Würzburg (DE)
  • University of Turin (IT)
  • Institut Gustave Roussy (FR)
Corresponding author
Hermsen, Ilse G.
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2011-06
Volume
96
Issue
6
Pages
1844-1851
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2010-2676
OpenAlex
W1995124360
Cited by
173
References
36
Citations by year
2026: 2 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 10 · 2021: 11 · 2020: 16 · 2019: 12 · 2018: 16 · 2017: 8 · 2016: 15 · 2015: 13 · 2014: 17 · 2013: 14 · 2012: 18
FWCI
17.99
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
Keywords
adrenocortical carcinoma, mitotane, o,p'-DDE, plasma drug concentration, therapeutic drug monitoring, tumor response prediction, survival, dose-response relationship, cut-off values, predictive biomarkers
MeSH terms
Adrenal Cortex Neoplasms, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mitotane, Predictive Value of Tests, Retrospective Studies, Sensitivity and Specificity, Adrenocortical Carcinoma, Antineoplastic Agents, Hormonal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review